We selected 38 melanoma cell lines, corresponding to the three major groups of mutations in melanoma: BRAF mutant, NRAS mutant, and NF1 mutant melanomas7 (Supplementary Table 1), and evaluated their sensitivity to the EPE peptide according to the percentage of viability of EPE-treated cells compared to Scrambled (Scr) peptide control: Sensitive (below 60%), partial response (60%-80%) and resistant (above 80%) (Fig. 1). The gene discussed is BRAF; the disease is melanoma.